GT Biopharma

GT Biopharma's corporate predecessor was Diagnostic Data, which became DDI Pharmaceuticals, merged with International BioClinical and Bioxytech, and took the name OXIS International; OXIS International later changed its name to GT Biopharma. OXIS International developed technologies and products to research, diagnose, treat, and prevent diseases of oxidative stress and inflammation associated with damage from free radical and reactive oxygen species. GT Biopharma is a clinical-stage immuno-oncology company developing therapies based on its proprietary NK cell engager (TriKE) technology.

GT Biopharma sets its TriKE molecules apart from full-length tri-specific antibodies with small single-chain fusion proteins whose nanobody arms bind the CD16 receptor of natural killer cells. Its GTB-3650 is being evaluated in relapsed or refractory CD33-expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.